NO20060328L - Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser - Google Patents

Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser

Info

Publication number
NO20060328L
NO20060328L NO20060328A NO20060328A NO20060328L NO 20060328 L NO20060328 L NO 20060328L NO 20060328 A NO20060328 A NO 20060328A NO 20060328 A NO20060328 A NO 20060328A NO 20060328 L NO20060328 L NO 20060328L
Authority
NO
Norway
Prior art keywords
acute
treatment
ache inhibitor
neurological disorders
combination
Prior art date
Application number
NO20060328A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Johannes Woltering
Erwin Goetschi
Theresa Maria Ballard
Silvia Gatti Mcarthur
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060328(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20060328L publication Critical patent/NO20060328L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20060328A 2003-07-25 2006-01-20 Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser NO20060328L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03016968 2003-07-25
PCT/EP2004/008020 WO2005014002A1 (en) 2003-07-25 2004-07-17 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders

Publications (1)

Publication Number Publication Date
NO20060328L true NO20060328L (no) 2006-02-17

Family

ID=34130033

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060328A NO20060328L (no) 2003-07-25 2006-01-20 Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser

Country Status (27)

Country Link
US (1) US7235547B2 (zh)
EP (1) EP1651234B1 (zh)
JP (1) JP5005343B2 (zh)
KR (1) KR100764330B1 (zh)
CN (1) CN1856312A (zh)
AR (1) AR045926A1 (zh)
AT (1) ATE374030T1 (zh)
AU (1) AU2004262897B9 (zh)
BR (1) BRPI0412919A (zh)
CA (1) CA2532347C (zh)
CO (1) CO5640124A2 (zh)
DE (1) DE602004009195T2 (zh)
DK (1) DK1651234T3 (zh)
ES (1) ES2293287T3 (zh)
HR (1) HRP20070552T3 (zh)
IL (1) IL173131A (zh)
MX (1) MXPA06000705A (zh)
MY (1) MY138394A (zh)
NO (1) NO20060328L (zh)
NZ (1) NZ544719A (zh)
PL (1) PL1651234T3 (zh)
PT (1) PT1651234E (zh)
RU (1) RU2357734C2 (zh)
SI (1) SI1651234T1 (zh)
TW (1) TW200524614A (zh)
WO (1) WO2005014002A1 (zh)
ZA (1) ZA200600693B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2472475C2 (ru) * 2010-04-20 2013-01-20 Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) Способ комбинированного лечения глаукомной оптической нейропатии
SG11201503192XA (en) 2012-10-23 2015-06-29 Hoffmann La Roche Mglu2/3 antagonists for the treatment of autistic disorders
BR112016021727A2 (pt) 2014-04-23 2017-08-15 Hoffmann La Roche Antagonistas de mglu2/3 para o tratamento de incapacidades intelectuais
CN112462047B (zh) * 2020-11-13 2023-02-07 北京元恩生物技术有限公司 一种尼卡巴嗪检测试剂盒及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
AU4498799A (en) * 1998-06-22 2000-01-10 Neurosearch A/S Method of preparing 5- or 8-bromoisoquinoline derivatives
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
SI1224174T1 (en) * 1999-10-15 2003-12-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
CN1199954C (zh) * 1999-10-15 2005-05-04 弗·哈夫曼-拉罗切有限公司 苯并二氮杂䓬衍生物
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
EP1203584A1 (en) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
US6500972B2 (en) * 2001-01-03 2002-12-31 Chinese Petroleim Corp. Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts
US6500955B1 (en) * 2001-02-02 2002-12-31 National Institute Of Pharmaceutical Education And Research One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate
CN100390235C (zh) * 2001-04-09 2008-05-28 富士胶片株式会社 偶氮化合物及其生产方法、中间体化合物和利用该化合物生产偶氮化合物的方法
CZ20033002A3 (cs) * 2001-04-12 2004-03-17 F. Hoffmann-La Roche Ag Deriváty dihydrobenzo [b] [1,4]diazepin-2-onu jako antagonisty mGluR2
DE60205100T2 (de) * 2001-04-12 2006-06-01 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
JP5005343B2 (ja) 2012-08-22
RU2006105721A (ru) 2007-09-10
IL173131A (en) 2010-12-30
EP1651234B1 (en) 2007-09-26
AU2004262897B9 (en) 2009-12-17
RU2357734C2 (ru) 2009-06-10
HRP20070552T3 (en) 2008-05-31
MXPA06000705A (es) 2006-04-11
KR20060037404A (ko) 2006-05-03
SI1651234T1 (sl) 2008-02-29
PT1651234E (pt) 2007-12-28
BRPI0412919A (pt) 2006-09-26
DE602004009195T2 (de) 2008-06-26
CN1856312A (zh) 2006-11-01
WO2005014002A1 (en) 2005-02-17
KR100764330B1 (ko) 2007-10-05
ATE374030T1 (de) 2007-10-15
EP1651234A1 (en) 2006-05-03
DE602004009195D1 (de) 2007-11-08
AR045926A1 (es) 2005-11-16
ES2293287T3 (es) 2008-03-16
AU2004262897A1 (en) 2005-02-17
US7235547B2 (en) 2007-06-26
JP2007504096A (ja) 2007-03-01
PL1651234T3 (pl) 2008-02-29
NZ544719A (en) 2009-04-30
CA2532347C (en) 2012-03-27
US20050049243A1 (en) 2005-03-03
IL173131A0 (en) 2006-06-11
MY138394A (en) 2009-05-29
AU2004262897B2 (en) 2009-08-20
CO5640124A2 (es) 2006-05-31
CA2532347A1 (en) 2005-02-17
ZA200600693B (en) 2007-05-30
DK1651234T3 (da) 2008-01-28
TW200524614A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
BRPI0516132A (pt) compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
TW200510416A (en) P38 inhibitors and methods of use thereof
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
WO2005000298A3 (en) 5-membered heterocycle-based p-38 inhibitors
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
TW200716561A (en) P38 inhibitors and methods of use thereof
TW200621261A (en) Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
WO2005009340A3 (en) Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
HUP0401633A2 (hu) Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására
IL175358A0 (en) 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
AR020740A1 (es) Composicion y metodo para tratar enfermedades alergicas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application